Ovid Therapeutics Announces Multiple Presentations at the American Academy of Neurology 2020 Annual Meeting
06 March 2020 - 8:06AM
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company
committed to developing medicines that transform the lives of
people with rare neurological diseases, today announced multiple
poster presentations across its rare neurological disease platform
at the American Academy of Neurology (AAN) 2020 Annual Meeting in
Toronto (April 25-May 1).
“We are pleased by the breadth of data selected for presentation
at this year’s AAN conference, which underscores our efforts to
find treatments for patients living with rare neurological
conditions like Angelman syndrome, Fragile X syndrome and rare
epilepsies,” said Amit Rakhit, M.D., MBA, President and Chief
Medical Officer at Ovid. “We look forward to joining world-renowned
neurologists and researchers attending AAN to present our findings
and continue to push the envelope in the name of patients and their
families, who inspire us every day.”
AAN 2020 Annual Meeting Presentation
Details
Presentations on OV101 (gaboxadol) in Neurodevelopmental
Disorders:
Title: The adaptation and utility of the
Clinical Global Impression scale for studying treatment outcomes in
neurodevelopmental conditions Poster No.: 009
Poster Session 5: Research Methodology, Education,
and History Date and Time: Monday, April 27,
8:00 – 9:00 a.m. ET
Title: The pivotal Phase 3 NEPTUNE trial
investigating gaboxadol in Angelman syndrome: Study design
Poster No.: 015 Poster Session
13: Neuromuscular and Clinical Neurophysiology (EMG)
Date and Time: Wednesday, April 29, 5:30 –
6:30 p.m. ET
Title: Evidence of pharmacodynamic tolerance
during repeated daily gaboxadol exposure in individuals with
Angelman syndrome Poster No.: 011 Poster
Session 13: Neuromuscular and Clinical Neurophysiology
(EMG) Date and Time: Wednesday, April 29,
5:30 – 6:30 p.m. ET
Title: Physiologically based pharmacokinetic
modeling (PBPK) for gaboxadol exposure in children with Angelman
syndrome Poster No.: 012 Poster Session
13: Neuromuscular and Clinical Neurophysiology (EMG)
Date and Time: Wednesday, April 29, 5:30 –
6:30 p.m. ET
Title: Caregiver insight on the core domains in
Angelman syndrome Poster No.: 013 Poster
Session 13: Neuromuscular and Clinical Neurophysiology
(EMG) Date and Time: Wednesday, April 29,
5:30 – 6:30 p.m. ET
Title: Quality of life in adolescent and adult
individuals with Angelman syndrome: Baseline results from the Phase
2 STARS study Poster No.: 014 Poster
Session 13: Neuromuscular and Clinical Neurophysiology
(EMG) Date and Time: Wednesday, April 29,
5:30 – 6:30 p.m. ET
Title: Concomitant medication in adolescent and
adult individuals with Angelman syndrome: Baseline results from the
Phase 2 STARS study Poster No.: 011 Poster
Session 14: Neuromuscular and Clinical Neurophysiology
(EMG) Date and Time: Thursday, April 30, 8:00
– 9:00 a.m. ET
Title: The Phase 2a ROCKET trial investigating
gaboxadol in adolescents and young adults with Fragile X syndrome:
Study design Poster No.: 003 Poster
Session 14: Neuromuscular and Clinical Neurophysiology
(EMG) Date and Time: Thursday, April 30, 8:00
– 9:00 a.m. ET
Presentations on OV935/TAK935 (soticlestat) in Rare
Developmental and Epileptic Encephalopathies (DEE):
Title: Initial data from the ongoing ENDYMION
open-label extension trial of soticlestat (TAK-935/OV935) in
participants with developmental and/or epileptic encephalopathies
(DEE) Poster No.: 007 Poster Session
10: Practice, Policy, and Ethics Date and
Time: Tuesday, April 28, 5:30 – 6:30 p.m. ET
Title: A Phase 1b/2a study of soticlestat
(TAK-935/OV935) as adjunctive therapy in adults with developmental
and/or epileptic encephalopathies (DEE) Poster
No.: 008 Poster Session 10: Practice,
Policy, and Ethics Date and Time: Tuesday, April
28, 5:30 – 6:30 p.m. ET
About Ovid TherapeuticsOvid Therapeutics Inc.
is a New York-based biopharmaceutical company using its
BoldMedicine® approach to develop medicines that transform the
lives of patients with rare neurological disorders. Ovid has a
broad pipeline of potential first-in-class medicines. The company’s
most advanced investigational medicine, OV101 (gaboxadol), is
currently in clinical development for the treatment of Angelman
syndrome and Fragile X syndrome. Ovid is also developing
OV935/TAK935 (soticlestat) in collaboration with Takeda
Pharmaceutical Company Limited for the potential treatment of rare
developmental and epileptic encephalopathies (DEE).
For more information on Ovid, please visit
http://www.ovidrx.com/.
Contacts
Investors and Media:Ovid Therapeutics
Inc.Investor Relations & Public Relationsirpr@ovidrx.com
Or
Investors: Steve KlassBurns McClellan,
Inc.sklass@burnsmc.com(212) 213-0006
Media: Katie Engleman 1AB katie@1abmedia.com
(919) 333-7722
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Apr 2024 to May 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From May 2023 to May 2024